t
IXICO plc provided a half-year trading update for the six months ended March 31, 2026, reporting expected revenues up 23% to £3.9 million and a gross margin increase to 53%. The company anticipates an order book of £18.1 million, a 38% increase from H1 2025, an EBITDA loss of £0.5 million, and a cash position of £1.7 million. On March 31, 2026, IXICO announced a £10 million capital raise (£9.4 million after costs), and its interim results will be released on May 19, 2026.
| Date | 21 Apr 2026 |
| Time | 07:00:05 |
| Category | Trading updates |
| ID | 2090B |
Half-year Trading update and Notice of Interim Results
Continued strong growth in first six months of trading in line with full-year expectations
21 April 2026: IXICO plc (AIM: IXI), IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today provides a trading update ahead of its interim results for the six months ended 31 March 2026.
Key metrics:
· Revenues expected to be up 23% to £3.9 million (H1 2025: £3.2m), driven by new contract wins, contract extensions and an increased volume of analyses in H12026 relative to the equivalent prior period.
· Gross margin expected to increase to 53% (H1 2025: 50%).
· Order book* expected to be £18.1 million; an increase of 38% on 31 March 2025 (H1 2025: £13.1m) and 31% on 30 September 2026 (FY 2025: £13.8m).
· Loss before interest, tax, depreciation and amortization expected to be £0.5 million (H1 2025: £0.7m loss); reflecting increased revenues, offset by full period impact of investments made in the Company's Innovate, Lead, Scale strategy to deliver sustained revenue growth.
· Cash position of £1.7 million (H1 2025: £5.0m).
· The Group announced a capital raise of £10 million (£9.4 million after placing costs) on 31 March 2026 to support the Group's Tech Bio strategy to partner its IXITM platform within the wider infrastructure of CROs, CTMS and, ultimately, Clinical Healthcare providers.
*Order book refers to those client contracts that have been signed by the Group but not yet delivered.
Notice of Results
The Company's first half results will be released on 19 May 2026. Bram Goorden (CEO) and Grant Nash (CFO) will provide a live presentation to all existing and potential shareholders relating to the Interim Results and the Company's progress and ongoing strategy via:
The Investor Meet Company platform on 19 May 2025 at 16:30 BST.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 09:00 BST on 18 May 2026, or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet IXICO PLC via:
https://www.investormeetcompany.com/ixico-plc/register-investor
Investors who already follow IXICO PLC on the Investor Meet Company platform will automatically be invited.
A recording of the results presentation will be made available on the Group's website.
Bram Goorden, CEO of IXICO, said: "The first half of the 2026 financial year saw strong continued revenue growth driven by new contract wins and extensions, and increased biomarker analysis activity. This momentum, combined with improved operational leverage, has delivered an increase in gross margin while our order book has also grown significantly, providing good visibility of future revenues. While we continue to invest for growth, we have reduced our EBITDA loss year-on-year, demonstrating progress towards profitability. I am also very excited about the recently announced capital raise which aims at deriving increased value from our IXITM platform as a premium technology."
Ends
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the UK version of the EU Market Abuse Regulation 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018, as amended and supplemented from time to time. Upon the publication of this announcement, this inside information is now considered to be in the public domain.
For further information please contact:
|
IXICO plc |
+44 (0) 20 3763 7499 |
|
Grant Nash, Chief Financial Officer James Chandler, Chief Business Officer |
|
|
Cavendish Capital Markets Limited (Nominated Adviser and Sole Broker) |
+44 (0) 20 7220 0500 |
|
Giles Balleny, Isaac Hooper (Corporate Finance) Nigel Birks (Healthcare Specialist Sales) Harriet Ward (Corporate Broking) Michael F Johnson (Sales) |
|
About IXICO www.IXICO.com
IXICO is a global leader in neuroscience imaging and biomarker analytics, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring. As a key part of the global neurological disease research community, the Company has built a global reputation and 20-year track record as an end-to-end Imaging Contract Research Organisation (iCRO) working with leading pharma companies, innovative biotechs, disease consortia and non-profit organisations. IXICO has supported hundreds of neurological clinical trials, analysed hundreds of thousands of scans and built an expansive network of expert imaging centres around the world.
The IXITM platform is tailor-made for neurological disease, reliably processing data from global trials, precisely measuring key imaging biomarkers associated with the identification, progression and treatment of diseases such as Alzheimer's, Huntington's and Parkinson's. Image data is interrogated by the platform and IXICO's expert scientists translating complex data into clinically meaningful while minimizing data variability and increasing reproducibility.